Article
Effect of dapagliflozin on diabetic patients with cardiovascular disease via MAPK signalling pathway
14 Jul 2021
Abstract excerpt
Clinical studies have shown that dapagliflozin can reduce cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM), but the exact mechanism is unclear. In this study, we used the molecular docking and network pharmacology methods to explore the potential mechanism of dapagliflozin on T2DM complicated with cardiovascular diseases (CVD). Dapagliflozin's potential targets were predicted via the Swiss...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
